Biocom Purchasing Group, a subsidiary of Biocom that accelerates life science success by leveraging innovative, member-driven strategic sourcing solutions that significantly lower the total cost of doing business, today announced a new program with Everlywell to offer at-home sample coll
|
SAN DIEGO and LOS ANGELES and SOUTH SAN FRANCISCO, Calif., Oct. 27, 2020 /PRNewswire/ -- Biocom Purchasing Group, a subsidiary of Biocom that accelerates life science success by leveraging innovative, member-driven strategic sourcing solutions that significantly lower the total cost of doing business, today announced a new program with Everlywell to offer at-home sample collection COVID-19 test kits and reporting to all Biocom members who may need testing, regardless of company size.
Biocom Purchasing Group today announced a new program with Everlywell to offer at-home COVID-19 test kits and reporting.
Biocom's program serves to extend effective, well-established and easy-to-perform self-collection nasal swab testing to over 1,300 members across the state under the Food and Drug Administration (FDA)'s Emergency Use Authorization (EUA) framework. Test purchases come equipped with Everlywell Lens, a comprehensive reporting dashboard for human resource representatives, which gives organizations visibility into the status of individual kits, from registration to results. "Traditionally, this kind of testing solution is not accessible for companies with fewer than 500 employees," said Rick Fultz, chief business officer of Biocom. "Everlywell testing kits will be instrumental in our members' ability to get tested from the safety of their own home for COVID-19 and ensure secure digital results within 24-72 hours of the lab receiving their sample. We are eager for our members to begin taking advantage of this new partnership with one of the national leaders in at-home collection lab testing." The program with Everlywell, which launches today, will provide Biocom members access to rt-PCR tests that will determine the presence or absence of RNA from the SARS-CoV-2-virus. Met with the highest standards of quality, safety, and reliability, Everlywell's straightforward sample collection, free shipping, and physician-reviewed results and insights ensure that we are connecting our members with one of the best testing solutions in the market. The laboratories used by Everlywell are CLIA-certified and many are CAP-accredited, which means they must meet or exceed high precision, accuracy, and validity standards, obtain both state and federal certifications, and submit themselves to regular inspections as well as independent third-party performance verifications. To learn more about the program or to request an order of Covid-19 test kits, please visit www.biocom.org/what-we-offer/purchasing-group/savings-portfolio/everlywell. About Biocom Purchasing Group About Everlywell The Austin-based company was founded in 2015 and is advised by a Scientific Advisory Board that includes some of the nation's top scientists from Harvard, MIT, Google and NYU. Everlywell was selected as one of Fast Company's Most Innovative Companies in 2019. For more information please visit www.everlywell.com. Disclaimer: This home collection kit has not been FDA cleared or approved. It has been authorized by the FDA under an EUA for the home collection and maintenance of nasal swab specimens as an aid in detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This home collection kit in combination with the authorized test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use.
SOURCE Biocom |
View original content to download multimedia:
